Prevention of Drug-Induced Risks

¹ Laboratoire Roche, Neuilly-sur-Seine, France
² CHU Henri Mondor, Créteil, France
³ Service des Maladies Vasculaires et Pharmacologie Clinique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Received: 20 May 2003
Accepted: 4 June 2003

Abstract

Effective prevention of drug-induced risks depends on an accurate understanding of their triggering or predisposing factors, and the quality of information on these available to prescribing practitioners and users. All preclinical and clinical data available on the proprietary medicinal product concerned should facilitate identification of a risk, and these data should be compared with existing data on drugs sharing the same mode of action or therapeutic strategy. This information should be based on a communication plan adapted to the context of the disease under treatment, the therapeutic alternatives available and the benefits expected.